Antimicrobial resistance crisis: could artificial intelligence be the solution?

Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed. The discovery and introduction of novel antibiotics are time-consuming and expensiv...

Full description

Saved in:
Bibliographic Details
Published in:Military medical research 2024-01, Vol.11 (1), p.7-7, Article 7
Main Authors: Liu, Guang-Yu, Yu, Dan, Fan, Mei-Mei, Zhang, Xu, Jin, Ze-Yu, Tang, Christoph, Liu, Xiao-Fen
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotic
Antibiotics
Antimicrobial agents
Antimicrobial peptide
Artificial Intelligence
Artificial intelligence (AI)
Bacteria
Bacterial infections
Clinical development
Cytotoxicity
Drug development
Drug dosages
Drug resistance
Drug Resistance, Bacterial
FDA approval
Gram-negative bacteria
Health care
Humans
Machine learning (ML)
Pathogens
Phage therapy
Pharmaceutical industry
Public Health
Review
Staphylococcus infections
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed. The discovery and introduction of novel antibiotics are time-consuming and expensive. According to WHO's report of antibacterial agents in clinical development, only 18 novel antibiotics have been approved since 2014. Therefore, novel antibiotics are critically needed. Artificial intelligence (AI) has been rapidly applied to drug development since its recent technical breakthrough and has dramatically improved the efficiency of the discovery of novel antibiotics. Here, we first summarized recently marketed novel antibiotics, and antibiotic candidates in clinical development. In addition, we systematically reviewed the involvement of AI in antibacterial drug development and utilization, including small molecules, antimicrobial peptides, phage therapy, essential oils, as well as resistance mechanism prediction, and antibiotic stewardship.
ISSN:2054-9369
2095-7467
2054-9369
DOI:10.1186/s40779-024-00510-1